Brokerages Set Lion Biotechnologies Inc. (LBIO) PT at $19.90
Lion Biotechnologies Inc. (NASDAQ:LBIO) has earned a consensus rating of “Buy” from the eight brokerages that are presently covering the company. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $19.90.
Several equities research analysts have recently weighed in on the company. Chardan Capital set a $20.00 target price on Lion Biotechnologies and gave the stock a “buy” rating in a research report on Sunday, August 21st. Cowen and Company reaffirmed a “buy” rating on shares of Lion Biotechnologies in a research report on Friday, November 4th. Zacks Investment Research downgraded Lion Biotechnologies from a “buy” rating to a “hold” rating in a research report on Tuesday, August 9th. Jefferies Group reaffirmed a “buy” rating and issued a $13.00 target price on shares of Lion Biotechnologies in a research report on Monday, November 7th. Finally, Roth Capital reiterated a “buy” rating and issued a $15.00 price target on shares of Lion Biotechnologies in a research note on Friday, August 26th.
Lion Biotechnologies (NASDAQ:LBIO) opened at 7.35 on Tuesday. The stock’s market capitalization is $456.33 million. The firm has a 50 day moving average price of $6.76 and a 200 day moving average price of $7.58. Lion Biotechnologies has a 52 week low of $4.24 and a 52 week high of $9.58.
TRADEMARK VIOLATION NOTICE: This news story was first reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The original version of this news story can be read at https://www.thecerbatgem.com/2016/11/27/brokerages-set-lion-biotechnologies-inc-lbio-pt-at-19-90.html.
Hedge funds have recently made changes to their positions in the stock. KCG Holdings Inc. purchased a new stake in shares of Lion Biotechnologies during the third quarter valued at about $101,000. Quantitative Investment Management LLC purchased a new stake in shares of Lion Biotechnologies during the second quarter valued at about $117,000. Stevens Capital Management LP purchased a new stake in shares of Lion Biotechnologies during the third quarter valued at about $118,000. TD Asset Management Inc. purchased a new stake in shares of Lion Biotechnologies during the third quarter valued at about $123,000. Finally, Geduld E E boosted its stake in shares of Lion Biotechnologies by 50.0% in the third quarter. Geduld E E now owns 15,000 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 5,000 shares during the last quarter. Hedge funds and other institutional investors own 79.02% of the company’s stock.
Lion Biotechnologies Company Profile
Lion Biotechnologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing and commercializing cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead pipeline candidate, LN-144, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma.
Receive News & Stock Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related stocks with our FREE daily email newsletter.